Track topics on Twitter Track topics that are important to you
DEER PARK, Ill., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the second quarter ended June 30, 2019 and provided an update on business progress.
“We made significant progress in the second quarter expanding and advancing our portfolio of late-stage product candidates, including the acquisition of ET-105, which added an additional high-value, near-term product launch to our portfolio,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals. “We are at an exciting inflection point as we anticipate becoming a commercial revenue generating company in the coming months. Our team is focused on preparing our commercial operations for the potential approvals of ET-202, our ready-to-use phenylephrine injection, in October of this year and ET-105, our patent-pending lamotrigine candidate, in March of 2020. We are also pleased to announce for the first time today that ET-203’s NDA has been submitted to the FDA, and if approved, could provide an additional mid-2020 product launch.”
Recent Business Milestones and Updates:
Potential Upcoming Business Milestones:
Eton currently has four products submitted to the FDA and seven additional product candidates in late-stage development, three of which are expected to be submitted to the FDA before year end:
ET-104: Eton expects bioequivalence study results by September 2019. If the study is successful, Eton expects to submit an NDA for ET-104 in the fourth quarter of 2019.
DS-300: DS-300 was previously submitted to the FDA as an NDA under a Rolling Review. As previously disclosed, the FDA has requested that Eton re-file the DS-300 application as an ANDA due to the approval of a competing product with the same molecule. Eton remains in discussions with the FDA for clarity on the pathway. If the application is required to be re-filed as an ANDA, Eton expects to submit the application before year end.
ET-103: Eton expects bioequivalence study results by September 2019. If the study is successful, Eton expects to submit an NDA for ET-103 in the fourth quarter of 2019.
|Product (Molecule)||Dosage Form||Category||Expected Submission Timing||Reference Product Market Size|
|ET-202 (Phenylephrine)||Injectable||Hospital||Submitted||$50 million +|
|ET-105 (Lamotrigine)||Oral Liquid||Neurology||Submitted||$700 million +|
|EM-100 (Ketotifen)||Ophthalmic||OTC***||Submitted||$50 million +|
|ET-203||Injectable||Hospital||Submitted||$90 million +|
|ET-104||Oral Liquid||Neurology||2019||$75 million +|
|DS-300||Injectable||Hospital||2019**||$75 million* +|
|ET-103 (Levothyroxine)||Oral Liquid||Endocrinology||2019||$2.5 billion +|
|DS-100||Injectable||Hospital||2020||$100 million* +|
|ET-101||Oral Liquid||Neurology||2020||$800 million +|
|ET-102||Oral Liquid||Neurology||2020||$100 million +|
|ET-201||Injectable||Injectable||2020||$10 million +|
|Note: Reference product market sizes based on IQVIA data unless noted.|
*Based on management estimates
** Product was previously submitted as an NDA. The FDA has requested resubmission as an ANDA
*** Bausch Health acquired U.S Rights and will be responsible for commercialization
Second Quarter Financial Results
Revenue: Eton reported no revenue in the second quarter of 2019 and no revenue for the same period in 2018.
Research and Development (R&D) Expenses: R&D expenses were $1.4 million for the second quarter of 2019 versus $1.7 million for the same period in 2018. The decline was primarily driven by reduced product-specific development costs in the period, partially offset by increased costs associated with headcount and the operation of the company’s R&D laboratory facility that was set up in late 2018.
General and Administrative (G&A) Expenses: G&A expenses were $1.9 million for the second quarter of 2019 versus $1.0 million for the same period in 2018. The increase was primarily driven by higher employee-related costs from increased headcount, public company expenses, and marketing expenses associated with product launch preparation activities. Excluding non-cash expenses, G&A expenses for the quarter were $1.5 million versus $0.6 million in the prior year period.
Net Loss: Eton reported a net loss for the second quarter of 2019 of $3.2 million versus $3.1 million for the same period of 2018.
Cash Position: As of June 30, Eton reported cash and cash equivalents of $14.9 million compared to $26.7 million as of December 31, 2018 and $19.6 million as of March 31, 2019. Subsequent to the quarter-end, in early July, Eton received a $1.3 million refund from the FDA for an NDA filing fee which had been paid in March 2019.
Conference Call and Webcast Information:
Eton Pharmaceuticals will host a conference call and webcast today at 4:30 p.m. ET (3:30 p.m. CT). To access the conference call, please dial 1-866-795-8473 (domestic) or 1-470-495-9161 (international)and refer to conference ID 4659811. The webcast can be accessed under “Events & Presentations” in the Investors section of the Company’s website at https://ir.etonpharma.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing the FDA’s 505(b)(2) regulatory pathway. Eton is primarily focused on liquid dosage forms including injectables, oral liquids and ophthalmics. Eton has a diversified pipeline of high-value product candidates in various stages of development and therapeutic areas, including multiple product candidates currently pending regulatory approval with the FDA.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Eton Pharmaceuticals, Inc.
Condensed Statements of Operations
(In thousands, except per share amounts)
|For the three months ended||For the six months ended|
|June 30, 2019||June 30, 2018||June 30, 2019||June 30, 2018|
|Research and development||1,439||1,707||7,904||2,981|
|General and administrative||1,910||990||3,499||2,680|
|Total operating expenses||3,349||2,697||11,403||5,661|
|Loss from operations||(3,349||)||(2,697||)||(10,903||)||(5,661||)|
|Other income (expense):|
|Interest and other income, net||100||28||244||57|
|Change in fair value of warrant liability||—||(413||)||—||(496||)|
|Loss before income tax expense||(3,249||)||(3,082||)||(10,659||)||(6,100||)|
|Income tax expense||—||—||—||—|
|Accrued dividends on redeemable convertible preferred stock||—||(304||)||—||(600||)|
|Deemed dividends for accretion of redeemable convertible preferred stock issuance costs||—||(418||)||—||(828||)|
|Net loss attributable to common stockholders||$||(3,249||)||$||(3,804||)||$||(10,659||)||$||(7,528||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.18||)||$||(0.79||)||$||(0.61||)||$||(1.80||)|
|Weighted average number of common shares outstanding, basic and diluted||17,733||4,786||17,618||4,172|
Eton Pharmaceuticals, Inc.
Condensed Balance Sheets
(in thousands, except share and per share amounts)
|June 30, 2019||December 31, 2018|
|Cash and cash equivalents||$||14,947||$||26,735|
|Prepaid expenses & other current assets||1,808||767|
|Total current assets||16,755||27,502|
|Property and equipment, net||1,223||773|
|Operating lease right-of-use assets, net||222||—|
|Other long-term assets, net||44||52|
|Liabilities and stockholders’ equity|
|Total current liabilities||1,459||2,024|
|Operating lease liabilities, net of current portion||86||—|
|Commitments and contingencies (Note 13)|
|Common stock, $0.001 par value; 50,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 17,763,045 and 17,607,928 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively||18||18|
|Additional paid-in capital||73,208||72,153|
|Total stockholders’ equity||16,699||26,303|
|Total liabilities and stockholders’ equity||$||18,244||$||28,327|
Eton Pharmaceuticals, Inc.
Condensed Statements of Cash Flows
|Six months ended June 30, 2019||Six months ended|
June 30, 2018
|Cash flows from operating activities|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Depreciation and amortization||178||23|
|Change in fair value of warrant liability||—||496|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other assets||(1,052||)||(304||)|
|Net cash used in operating activities||(10,963||)||(4,078||)|
|Cash used in investing activities|
|Purchases of property and equipment||(1,030||)||(132||)|
|Cash flows from financing activities|
|Proceeds from employee stock purchase plan and stock option exercises||205||—|
|Net cash provided by financing activities||205||—|
|Change in cash and cash equivalents||(11,788||)||(4,210||)|
|Cash and cash equivalents at beginning of period||26,735||13,156|
|Cash and cash equivalents at end of period||$||14,947||$||8,946|
|Supplemental disclosures of cash flow information|
|Cash paid for interest||$||—||$||—|
|Cash paid for income taxes||$||—||$||—|
|Supplemental disclosures of non-cash investing and financing activities:|
|Accrued dividends on redeemable convertible preferred stock||$||—||$||600|
|Deemed dividends for accretion of redeemable convertible preferred stock issuance costs||$||—||$||828|
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...